Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

PROSTATE CANCER

Therapy-induced small-cell disease: from mouse to man and back

With the emergence of increasingly potent androgen deprivation therapy, rates of treatment-emergent small-cell neuroendocrine prostate cancer are increasing. In a recent prospective study, Aggarwal and colleagues defined the frequency and clinical and genomic characteristics of these tumours.

This is a preview of subscription content

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Transdifferentiation to treatment-induced small-cell neuroendocrine prostate cancer.

References

  1. 1.

    Nuhn, P. et al. Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology. Eur. Urol. https://doi.org/10.1016/j.eururo.2018.03.028 (2018).

    Article  PubMed  Google Scholar 

  2. 2.

    Davies, A. H., Beltran, H. & Zoubeidi, A. Cellular plasticity and the neuroendocrine phenotype in prostate cancer. Nat. Rev. Urol. 15, 271–286 (2018).

    CAS  Article  Google Scholar 

  3. 3.

    Mosquera, J. M. et al. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia 15, 1–10 (2013).

    CAS  Article  Google Scholar 

  4. 4.

    di Sant’Agnese, P. A. Neuroendocrine differentiation in human prostatic carcinoma. Hum. Pathol. 23, 287–296 (1992).

    Article  Google Scholar 

  5. 5.

    Aggarwal, R. et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J. Clin. Oncol. 36, 2492–2503 (2018).

    Article  Google Scholar 

  6. 6.

    Hu, C.-D., Choo, R. & Huang, J. Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure. Front. Oncol. 5, 90 (2015).

    Article  Google Scholar 

  7. 7.

    Bluemn, E. G. et al. Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling. Cancer Cell 32, 474–489 (2017).

    CAS  Article  Google Scholar 

  8. 8.

    Jin, R. J. et al. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Cancer Res. 64, 5489–5495 (2004).

    CAS  Article  Google Scholar 

  9. 9.

    Grabowska, M. M. et al. Mouse models of prostate cancer: picking the best model for the question. Cancer Metastasis Rev. 33, 377–397 (2014).

    CAS  Article  Google Scholar 

  10. 10.

    Gupta, A. et al. Neuroendocrine differentiation in the 12T-10 transgenic prostate mouse model mimics endocrine differentiation of pancreatic beta cells. Prostate 68, 50–60 (2008).

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Robert J. Matusik.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Grabowska, M.M., Matusik, R.J. Therapy-induced small-cell disease: from mouse to man and back. Nat Rev Urol 15, 662–663 (2018). https://doi.org/10.1038/s41585-018-0084-z

Download citation

Further reading

Search

Quick links